CŌRE Diagnostics collaborates with PredOmix to launch multi-cancer detection test for women

India-based CŌRE Diagnostics, a leading player in the health and diagnostics industry, has announced its collaboration with PredOmix Technologies, a startup based in Gurugram) to launch OncoVeryx-F, a ground-breaking multi-cancer detection test specifically designed for high-risk and asymptomatic women. 

Early-stage cancer detection is critical in improving treatment outcomes and saving lives, and OncoVeryx-F is set to revolutionise early-stage cancer detection and improve treatment outcomes.

OncoVeryx-F's ability to identify cancer at Stages 1 and 2 increases the likelihood of successful treatment, providing patients a better chance of recovery. With an impressive accuracy rate of 98%, OncoVeryx-F can detect the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test. This breakthrough technology offers a comprehensive screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer.

By offering a highly accurate and non-invasive screening tool, OncoVeryx-F aims to empower women and their healthcare providers to take proactive steps towards early intervention and personalised treatment plans.